134 related articles for article (PubMed ID: 15879696)
1. Insulin-like growth factor system in amyotrophic lateral sclerosis.
Wilczak N; Keyser J
Endocr Dev; 2005; 9():160-169. PubMed ID: 15879696
[TBL] [Abstract][Full Text] [Related]
2. Free insulin-like growth factor (IGF)-I and IGF binding proteins 2, 5, and 6 in spinal motor neurons in amyotrophic lateral sclerosis.
Wilczak N; de Vos RA; De Keyser J
Lancet; 2003 Mar; 361(9362):1007-11. PubMed ID: 12660059
[TBL] [Abstract][Full Text] [Related]
3. Insulin-like growth factor-I for the treatment of amyotrophic lateral sclerosis.
Sakowski SA; Schuyler AD; Feldman EL
Amyotroph Lateral Scler; 2009 Apr; 10(2):63-73. PubMed ID: 18608100
[TBL] [Abstract][Full Text] [Related]
4. Insulin-like growth factor-I: potential for treatment of motor neuronal disorders.
Lewis ME; Neff NT; Contreras PC; Stong DB; Oppenheim RW; Grebow PE; Vaught JL
Exp Neurol; 1993 Nov; 124(1):73-88. PubMed ID: 8282084
[TBL] [Abstract][Full Text] [Related]
5. The insulin-like growth factor signaling system and ALS neurotrophic factor treatment strategies.
Festoff BW; Yang SX; Vaught J; Bryan C; Ma JY
J Neurol Sci; 1995 May; 129 Suppl():114-21. PubMed ID: 7595601
[TBL] [Abstract][Full Text] [Related]
6. Recombinant human insulin-like growth factor I (rhIGF-I) for amyotrophic lateral sclerosis/motor neuron disease.
Mitchell JD; Wokke JH; Borasio GD
Cochrane Database Syst Rev; 2002; (3):CD002064. PubMed ID: 12137643
[TBL] [Abstract][Full Text] [Related]
7. Neurotrophic and Neuroregenerative Effects of GH/IGF1.
Bianchi VE; Locatelli V; Rizzi L
Int J Mol Sci; 2017 Nov; 18(11):. PubMed ID: 29149058
[TBL] [Abstract][Full Text] [Related]
8. Insulin-like growth factor 1 in diabetic neuropathy and amyotrophic lateral sclerosis.
Rauskolb S; Dombert B; Sendtner M
Neurobiol Dis; 2017 Jan; 97(Pt B):103-113. PubMed ID: 27142684
[TBL] [Abstract][Full Text] [Related]
9. The GH-IGF system in amyotrophic lateral sclerosis: correlations between pituitary GH secretion capacity, insulin-like growth factors and clinical features.
Pellecchia MT; Pivonello R; Monsurrò MR; Trojsi F; Longo K; Piccirillo G; Pivonello C; Rocco M; Di Somma C; Colao A; Tedeschi G; Barone P
Eur J Neurol; 2010 May; 17(5):666-71. PubMed ID: 20002733
[TBL] [Abstract][Full Text] [Related]
10. Therapeutic benefit of intrathecal injection of insulin-like growth factor-1 in a mouse model of Amyotrophic Lateral Sclerosis.
Nagano I; Ilieva H; Shiote M; Murakami T; Yokoyama M; Shoji M; Abe K
J Neurol Sci; 2005 Aug; 235(1-2):61-8. PubMed ID: 15990113
[TBL] [Abstract][Full Text] [Related]
11. Functional improvement in mouse models of familial amyotrophic lateral sclerosis by PEGylated insulin-like growth factor I treatment depends on disease severity.
Saenger S; Holtmann B; Nilges MR; Schroeder S; Hoeflich A; Kletzl H; Spooren W; Ostrowitzki S; Hanania T; Sendtner M; Metzger F
Amyotroph Lateral Scler; 2012 Sep; 13(5):418-29. PubMed ID: 22871074
[TBL] [Abstract][Full Text] [Related]
12. Distribution and levels of insulin-like growth factor (IGF-I and IGF-II) and insulin receptor binding sites in the spinal cords of amyotrophic lateral sclerosis (ALS) patients.
Doré S; Krieger C; Kar S; Quirion R
Brain Res Mol Brain Res; 1996 Sep; 41(1-2):128-33. PubMed ID: 8883943
[TBL] [Abstract][Full Text] [Related]
13. The peripheral insulin-like growth factor system in amyotrophic lateral sclerosis and in multiple sclerosis.
Torres-Aleman I; Barrios V; Berciano J
Neurology; 1998 Mar; 50(3):772-6. PubMed ID: 9521273
[TBL] [Abstract][Full Text] [Related]
14. The composition and distribution of insulin-like growth factors (IGFs) and IGF-binding proteins (IGFBPs) in the serum of growth hormone receptor-deficient patients: effects of IGF-I therapy on IGFBP-3.
Gargosky SE; Wilson KF; Fielder PJ; Vaccarello MA; Guevara-Aguirre J; Diamond FB; Baxter RC; Rosenbloom AL; Rosenfeld RG
J Clin Endocrinol Metab; 1993 Dec; 77(6):1683-9. PubMed ID: 7505289
[TBL] [Abstract][Full Text] [Related]
15. On the therapeutic potential for insulin-like growth factor use in motor neuron disease.
Ishii DN; Marsh DJ
Exp Neurol; 1993 Nov; 124(1):96-9. PubMed ID: 8282086
[No Abstract] [Full Text] [Related]
16. A placebo-controlled trial of insulin-like growth factor-I in amyotrophic lateral sclerosis. European ALS/IGF-I Study Group.
Borasio GD; Robberecht W; Leigh PN; Emile J; Guiloff RJ; Jerusalem F; Silani V; Vos PE; Wokke JH; Dobbins T
Neurology; 1998 Aug; 51(2):583-6. PubMed ID: 9710040
[TBL] [Abstract][Full Text] [Related]
17. The lack of effect of specific overexpression of IGF-1 in the central nervous system or skeletal muscle on pathophysiology in the G93A SOD-1 mouse model of ALS.
Messi ML; Clark HM; Prevette DM; Oppenheim RW; Delbono O
Exp Neurol; 2007 Sep; 207(1):52-63. PubMed ID: 17597610
[TBL] [Abstract][Full Text] [Related]
18. Recombinant human insulin-like growth factor-I in ALS: description of a double-blind, placebo-controlled study. North American ALS/IGF-I Study Group.
Lange DJ; Felice KJ; Festoff BW; Gawel MJ; Gelinas DF; Kratz R; Lai EC; Murphy MF; Natter HM; Norris FH; Rudnicki S
Neurology; 1996 Oct; 47(4 Suppl 2):S93-4; discussion S94-5. PubMed ID: 8858058
[No Abstract] [Full Text] [Related]
19. A review of the potential role of nano-enabled drug delivery technologies in amyotrophic lateral sclerosis: lessons learned from other neurodegenerative disorders.
Mazibuko Z; Choonara YE; Kumar P; Du Toit LC; Modi G; Naidoo D; Pillay V
J Pharm Sci; 2015 Apr; 104(4):1213-29. PubMed ID: 25559087
[TBL] [Abstract][Full Text] [Related]
20. Free insulin-like growth factor (IGF)-1 and IGF-binding proteins-2 and -3 in serum and cerebrospinal fluid of amyotrophic lateral sclerosis patients.
Corbo M; Lunetta C; Magni P; Dozio E; Ruscica M; Adobbati L; Silani V
Eur J Neurol; 2010 Mar; 17(3):398-404. PubMed ID: 19845745
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
